Programmed death-1 targeting can promote allograft survival

Area of Science:

• Immunology
• Transplantation Biology
• Molecular Medicine

Background:

• Programmed death-1 (PD-1) and its ligands (PD-L1, PD-L2) form an inhibitory pathway with therapeutic potential in immune-mediated diseases.
• Understanding PD-1 pathway dynamics in cardiac allograft rejection is crucial for developing new treatments.

Purpose of the Study:

• To investigate the expression and function of the PD-1 pathway in experimental cardiac allograft rejection.
• To evaluate the therapeutic efficacy of targeting PD-1 in prolonging allograft survival.

Main Methods:

• Examined PD-1, PD-L1, and PD-L2 expression in cardiac allografts during rejection and under various immunosuppressive therapies.
• Utilized PD-L1.Ig and PD-L2.Ig fusion proteins to inhibit PD-1 signaling in vivo.
• Assessed allograft survival, intragraft cytokine expression, and development of transplant arteriosclerosis.

Main Results:

• PD-1, PD-L1, and PD-L2 were upregulated within cardiac allografts during rejection, independent of cyclosporin A or rapamycin.
• PD-L1.Ig administration significantly prolonged cardiac allograft survival in CD28(-/-) recipients and in combination with immunosuppression.
• PD-L1.Ig therapy reduced intragraft IFN-gamma and chemokines and prevented transplant arteriosclerosis.

Conclusions:

• Targeting the PD-1 pathway, particularly with PD-L1.Ig, can effectively block cardiac allograft rejection.
• Combined PD-1 targeting with limited immunosuppression or submaximal signals modulates immune responses and promotes long-term graft survival.